Sugi Predict

Sugi Predict / Compounds / SCHEMBL837542

SCHEMBL837542

SCHEMBL837542

N[C@@H](Cc1c[nH]c2c(OCc3ccccc3)cccc12)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 2/20 0.65
▸ PLA2G2A P14555 2/20 0.65
▸ TRPM8 Q7Z2W7 1/20 0.65
▸ KMT2A Q03164 3/20 0.62
▸ MEN1 O00255 2/20 0.62
▸ HSP90AA1 P07900 1/20 0.62
▸ HSP90AB1 P08238 1/20 0.62
▸ KDM4E B2RXH2 2/20 0.57
▸ LMNA P02545 2/20 0.57
▸ MAPT P10636 2/20 0.57
▸ TSHR P16473 2/20 0.57
▸ BLM P54132 2/20 0.57
▸ PMP22 Q01453 2/20 0.57
▸ MPO P05164 1/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ TNF P01375 1/20 0.51
▸ ADRB3 P13945 4/20 0.51
▸ ALDH1A1 P00352 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ HTR1A P08908 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL837541 1.00 LTA4H (0.65) LTA4HPLA2G2ATRPM8KMT2AMEN1
Oxalic Acid SCHEMBL7571181 0.86 LTA4H (0.62) LTA4HPLA2G2ATRPM8KMT2AMEN1
SCHEMBL31688533 0.85 KMT2A (0.56) LTA4HPLA2G2ATRPM8KMT2AMEN1
SCHEMBL5859941 0.84 LTA4H (0.66) LTA4HPLA2G2ATRPM8KMT2AMEN1
SCHEMBL5859936 0.84 LTA4H (0.66) LTA4HPLA2G2ATRPM8KMT2AMEN1
SCHEMBL5481516 0.84 LTA4H (0.69) LTA4HPLA2G2ATRPM8MAPTADRB3
SCHEMBL5648360 0.84 LTA4H (0.69) LTA4HPLA2G2ATRPM8MAPTADRB3
SCHEMBL5480068 0.83 LTA4H (0.67) LTA4HPLA2G2ATRPM8ADRB3ADORA3
SCHEMBL1461102 0.83 KDM4E (0.59) LTA4HPLA2G2AKMT2AMEN1HSP90AA1
SCHEMBL18029023 0.83 KDM4E (0.59) LTA4HPLA2G2AKMT2AMEN1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 — — US disclosed
US-20250320253-A1 TRANSMEMBRANE PEPTIDIC ANTAGONISTS OF PLEXIN-A1 AND THEIR THERAPEUTIC USES UNIV STRASBOURG (FR) 2025-10-16 — — US disclosed
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF UNIVERSITY OF CONNECTICUT (US) 2025-10-02 — — US disclosed
US-20250229081-A1 NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF UNIVERSITY OF CONNECTICUT 2025-07-17 — — US disclosed
EP-4578868-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
EP-4578867-A1 CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR FUJIFILM Corporation (JP) 2025-07-02 — — EP disclosed
CN-120202010-A Ligand-oligonucleotide conjugates and linkers for use therewith 上海京新生物医药有限公司 2025-06-24 — — CN disclosed
US-20250179120-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM CORPORATION (JP) 2025-06-05 — — US disclosed
US-20250179119-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR FUJIFILM CORPORATION (JP) 2025-06-05 — — US disclosed
US-20250084410-A1 INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF Synthorx, Inc. (US) 2025-03-13 — — US disclosed
EP-1085891-A1 MULTIBINDING INHIBITORS OF TOPOISOMERASE Advanced Medicine, Inc. (US) 2001-03-28 — — EP disclosed
WO-2001019852-A2 METHODS OF PEPTIDE PREPARATION ALPHARMA AS (NO) 2001-03-22 — — WO disclosed
EP-0555537-B1 Endothelin antagonists BANYU PHARMA CO LTD (JP) 2000-11-02 — — EP disclosed
WO-2000012541-A2 CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 — — WO disclosed
WO-2000012542-A2 CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 — — WO disclosed
WO-1999064054-A9 MULTIBINDING INHIBITORS OF TOPOISOMERASE ADVANCED MEDICINE INC (US) 2000-03-02 — — WO disclosed
WO-1999064054-A1 MULTIBINDING INHIBITORS OF TOPOISOMERASE ADVANCED MEDICINE, INC. (US) 1999-12-16 — — WO disclosed
US-5614498-A OLIGOPEPTIDES, BRONCHDILATORS BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-03-25 — — US disclosed
US-5496928-A Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1996-03-05 — — US disclosed
EP-0555537-A2 Endothelin antagonistic substance BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179119-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR MLX, BMX, ADM2 LTA4H 4508/4885PLA2G2A 926/4885TRPM8 1421/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 LTA4H 2721/4885PLA2G2A 2568/4885TRPM8 3545/4885
US-20250302762-A1 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF JAK2, JAK1, CHMP4B LTA4H 3989/4885PLA2G2A 2180/4885TRPM8 4367/4885
US-20250179120-A1 CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR MDN1, MLX, BMX LTA4H 4465/4885PLA2G2A 894/4885TRPM8 1694/4885
US-20250084410-A1 INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF RNGTT, TRMT1, OSGEP LTA4H 3092/4885PLA2G2A 3481/4885TRPM8 4686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.